Sargent Investment Group LLC lessened its holdings in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 43.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 68,690 shares of the biopharmaceutical company's stock after selling 52,500 shares during the quarter. Sargent Investment Group LLC owned 0.64% of MediWound worth $1,066,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of the business. GAMMA Investing LLC raised its position in MediWound by 1,507.1% during the 1st quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 1,703 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of MediWound by 154.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 1,162 shares in the last quarter. Bank of America Corp DE raised its position in shares of MediWound by 38.0% in the 4th quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company's stock worth $141,000 after acquiring an additional 2,178 shares in the last quarter. MGO One Seven LLC acquired a new stake in shares of MediWound in the 4th quarter valued at about $216,000. Finally, Barclays PLC grew its stake in shares of MediWound by 11.2% in the 4th quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company's stock valued at $221,000 after buying an additional 1,249 shares during the period. Institutional investors and hedge funds own 46.83% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the company. Wall Street Zen downgraded MediWound from a "hold" rating to a "sell" rating in a research note on Friday. Oppenheimer assumed coverage on shares of MediWound in a report on Monday, June 2nd. They issued an "outperform" rating and a $34.00 price target on the stock. HC Wainwright set a $31.00 target price on shares of MediWound and gave the company a "buy" rating in a report on Thursday, May 22nd. Finally, Alliance Global Partners assumed coverage on shares of MediWound in a report on Friday, May 2nd. They set a "buy" rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $32.25.
Read Our Latest Stock Report on MDWD
MediWound Trading Up 2.0%
MediWound stock opened at $20.46 on Friday. The firm has a 50-day moving average of $20.25 and a 200-day moving average of $18.48. The firm has a market cap of $221.17 million, a P/E ratio of -9.79 and a beta of 0.32. MediWound Ltd. has a 1-year low of $14.14 and a 1-year high of $22.51.
MediWound (NASDAQ:MDWD - Get Free Report) last released its quarterly earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.58. MediWound had a negative net margin of 110.45% and a negative return on equity of 74.12%. The company had revenue of $3.96 million during the quarter, compared to the consensus estimate of $5.20 million. During the same period in the prior year, the firm earned ($1.05) earnings per share. Research analysts forecast that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.
MediWound Company Profile
(
Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
See Also
Want to see what other hedge funds are holding MDWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MediWound Ltd. (NASDAQ:MDWD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
